Jasper Therapeutics, Inc. (JSPR)

NASDAQ: JSPR · IEX Real-Time Price · USD
29.36
+0.54 (1.87%)
At close: Mar 28, 2024, 4:00 PM
30.99
+1.63 (5.55%)
After-hours: Mar 28, 2024, 7:50 PM EDT

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.

The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

The company is headquartered in Redwood City, California.

Jasper Therapeutics, Inc.
Jasper Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Ronald A. Martell

Contact Details

Address:
2200 Bridge Pkwy Suite #102
Redwood City, California 94065
United States
Phone (650) 549-1400
Website jaspertherapeutics.com

Stock Details

Ticker Symbol JSPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001788028
CUSIP Number 471871103
ISIN Number US4718712023
Employer ID 84-2984849
SIC Code 2836

Key Executives

Name Position
Ronald A. Martell President, Chief Executive Officer and Director
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Chair of Scientific Advisory Board and Director
Jeetinder Singh Mahal M.B.A. Chief Operating Officer
Herbert C. Cross Chief Financial Officer and Corporate Secretary
Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations
David Ku M.D. Vice President of Corporate Development, Portfolio Strategy and Management
Matthew Ford Vice President of Human Resources
Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research and Translational Medicine
Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer
Patricia Carlos Senior Vice President of Regulatory Affairs and Quality

Latest SEC Filings

Date Type Title
Mar 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 12, 2024 144 Filing
Mar 6, 2024 144 Filing
Mar 5, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 5, 2024 10-K Annual Report
Mar 4, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership